DexCom, Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? DexCom, Inc. trades at $89.08 (market cap $33.79B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.29. The key difference: DexCom, Inc. is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| DXCM | YMAG | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $89.53 | $15.98 |
52-Week Low | $54.84 | $10.76 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
YMAG trades at $11.33, down 2.24% today, with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, with recent payments ranging from $0.07 to $0.40 per share. Technical indicators show strong trend momentum with ADX readings above 25, while RSI suggests potential overbought conditions on shorter timeframes.
YMAG's option income strategy generates substantial distributions but faces NAV stability challenges during earnings periods. The fund's structure effectively monetizes volatility in rangebound markets, though concentrated exposure to Magnificent Seven stocks creates single-sector risk. Current price action tests key support at $11-$12 resistance levels.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →